Clotting, immune system, and venous thrombosis in lung adenocarcinoma patients: A prospective study

Cancer Investigation

Volumn 27, Issue 10, 2009, Pages 989-997

  De Meis, Ernesto ^a   Pinheiro, Vera R ^a   Zamboni, Mauro M ^a   Guedes, Maria Teresa S ^a   Castilho, Ilda A M ^a   Martinez, Maria Mercedes K ^a   Leda, Marys Stella O ^a   Silveira, Neura P R ^a   Rumjanek, Vivian M ^b   Levy, Roger A ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Antiphospholipid; Interleukin; Lung adenocarcinoma; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN M; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BIVARIATE ANALYSIS; BLOOD CLOTTING; CANCER PATIENT; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNE SYSTEM; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; VEIN THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD COAGULATION; CYTOKINES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 70450210544     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903124464     Document Type: Article

References (31)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. Cancer J Clin 2008, 58, 71-96.
2. National Cancer Institute. Cancer Statistics for 2008. Rio de Janeiro, Brazil: Brazilian health ministry/National Cancer Institute, 30-31.
3. Bloom, J.W.; Osanto, S.; Rosendal, F.R. The risk of a venous thrombotic event in lung cancer patients: Higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004, 2, 1760-1765.
4. Mason, D.P.; Quader, M.A.; Bloackstone, E.H.; Rajeswaran, J.; DeCamp, M.M.; Murthy, S.C.; Quader AK, Rice TW. Thromboembolism after pneumectomy formalignancy: An independent marker of poor outcome. J Thorac Cardiovasc Surg 2006, 131, 711-718.
5. Chew, H.K.;Wun, T.; Harvey, D.; Zhou, H.;White, R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Int Med 2006, 166, 458-464. (Pubitemid 43313651)
6. Buller, H.R.; Van Doormaal, F.F.; Van Sluis, G.L.; Kamphuisen, P.W. Cancer and thrombosis: From molecular mechanisms to clinical presentation. J Thromb Haemost 2007, 5(Suppl. 1), 246-254.
7. Sorensen, H.T.; Mellemkjǽr, L.; Olsen, J.H.; Baron, J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343, 1846-1850.
8. Fukuyama, T.; Ichiki, Y.; Yamada, S.; Shigematsu, Y.; Baba, T.; Nagata, Y.; Mizakami, M.; Sugaya, M.; Takenoyama, M.; Hanagiri, T.; Sugio, K.; Yasumoto, K. Cytokine production of lung cell line: Correlation between their production and the inflammatory/ immunological response both in vivo and in vitro. Cancer Sci 2007, 98, 1048-1054.
9. Peppelenbosch, M.P.; Versterg, H. Cell biology of tissue factor, an unusual member of the cytokine receptor family. Trends Cardiovasc Med 2001, 11, 335-339.
10. Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006, 97, 439-447.
11. Even-Ram, S.; Uziely, B.; Cohen, P.; Grisaru-Granousky, S.; Maoz, M.; Ginzburg, Y.; Reich, R., Vlodarsky, I., Bar-Shart, R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998, 4, 909-914.
12. Blanchon, F.; Grivaux, M.; Asselain, B.; Lebas, F.X.; Orlando, J.P.; Piquet, J.; Zureik, M. 4-year mortality in patients with non-small cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006, 7, 829-836.
13. Tripodi, A. Levels of coagulation factors and venous thromboembolism. Haematologica 2003, 88, 705-711.
14. Vergnolle, N.; Wallace, J.L.; Bunnett, N.W.; Hollanberg, M.D. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001, 22(3), 146-152.
15. Reittsma, P.H.; Rosendaal, F.R. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004, 2, 619-622.
16. Jullien, V.; Heudier, P.; Carŕe, Y.; Peyrade, F.; Taillan, B.; Tchiknavorian, X.; Chevallier, P.; Perrin, C.; Fuzibet, G., Dujardin, P. Bronchopulmonary cancer, antiphospholipid syndrome and coagulation disorders. Rev Ḿed Interne 1999, 20, 696-700.
17. Gomez Puerta, J.A.; Cervera, R.; Espinosa, G.; Aquiĺo, S.; Bucciarelli, S.; Ramos-Casals, M.; Ingelmo, M.; Asherson, R.A.; Font, J. Antiphospholipid antibodies associated with malignancies. Clinical and pathological characteristics of 120 patients. Semm Arthritis Rheum 2006, 35, 322-332.
18. Bairey, O.; Blickstein, D.; Monselise, Y.; Lahav, J.; Stark, P.; Prokocimer, M.; Nativ, H.M.; Kirgner, I.; Pazgal, I.; Shaklai, M. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin lymphoma. Eur J Haematol 2006, 76, 384-391.
19. Genvresse, I.; Lüftner, D.; Späth-Schwalbe, E.; Buttgereit, F. Prevalence and clinical significance of anticardiolipin and anti- â2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002, 68, 84-90.
20. Pierangeli, S.S.; Colden-Stanfield, M.; Liu, X.; Barker, J.H.; Anderson, G.L.; Harris, E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99, 1997-2002. (Pubitemid 29183897)
21. Cuadrado, M.J.; Lopez-Pedreira, C.; Khamashta, M.A.; Camps, M.T.; Tinahonas, F.; Torres, A.; Hughes, G.R.; Velasco, F. Thrombosis in primary antiphospholipid syndrome: A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40(5), 834-841.
22. Hua, Y.; Tang, L.; Keep, R.F.; Schallert, T.; Fewel, M.E.; Muraszko, K.M.; Hoff, J.T.; Xi, G. The role of thrombin in gliomas. J Thromb Haemost 2005, 3, 1917-1923.
23. Rickles, F.R.; Paterno, S.; Fernandez, P.M. Tissue Factor, thrombin and cancer. Chest 2003, 124, 58S-68S.
24. Lopez-Pedrera, C.; Buendia, P.; Cuadrado, M.J.; Siendones, E.; Aguine, M.A.; Barbarroja, N.; Montriel-Duarte, C.; Torres, A.; Khamashta, M.; Velasco, F. Antiphospholipid antibodies from patients with antiphospholipid syndrome induce monocyte Tissue Factor expression through the simultaneous activation of NKÊB/ Rel proteins via p38 mitogen-activated protein kinase pathway and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54(1), 301-311.
25. Scheller, J.; Ohnesorge, N.; Rose-John, S. Interleukin-6 transsignalling in chronic inflammation and cancer. Scand J Immunol 2006, 63, 321-329.
26. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P.G.; Anderson, K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7, 585-598.
27. Lowen, G.M.; Tracy, E.; Blanchard, F.; Tan, D.; Yu, J.; Raza, S.; Matsui, S.I.; Baumann, H. Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer 2005, 5, 145.
28. Espinosa, G.; Cervera, R.; Font, J.; Shoenfeld, Y. Antiphospholipid syndrome: Pathogenic mechanisms. Autoimmun Rev 2003, 2, 86-93.
29. Rand, J.H. The antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2007, 136-142.
30. Schwartz-Albiez, R.; Laban, S.; Eichmüller, S.; Kirschfink, M. Cytotoxic natural antibodies against human tumours; An option for anti-cancer immunotherapy? Autoimmun Rev 2008, 7, 491-495.
31. Miesbach, W.; Scharrer, I.; Asherson, R.A. High titres of IgMantiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkins lymphoma. Clin Rheumatol 2007, 26, 95-97.